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Conclusion: These results indicate that APD, currently used in DES, particularly
paciltaxel, impair EPC proliferation, function and render them prothrombotic. This
observation may provide a putative mechanism for late ST seen in DES recipients.
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Background: Coronary drug-eluting stent in - stent restenosis (DES ISR) is a growing
clinical problem that continues to be one of the most important limitations of PCI. We
used the Swedish angiography and angioplasty registry (SCAAR) to investigate
occurrence and results of treatment of DES ISR.
Methods: We evaluated results of treatment of in - stent restenosis in a very large
patient cohort of all consecutive coronary stent implantations in Sweden between
January 1, 2005 and October 06, 2010. The data were analyzed with regard to different
types of treatment, patient and stenosis characteristics. 142678 stents (bare metal and
drug eluted stens) were implanted and 2126 cases of PCI - treated DES – in- stent
restenosis were analyzed.
Results: 1. Neither repeated DES therapy, BMS implantation or plain balloon dilatation
is superior in the presence of a DES ISR. 2. Switching between different DES drug
coatings in the treatment of DES ISR with repeated DES implantation is not
advantageous.
Conclusion: There is so far no therapy of choice in the treatment of DES ISR.
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Background: Emphasis on DES-related outcomes has shifted temporally from early
to late occurring events with long-term follow-up identifying trends in safety and
efficacy that may distinguish DES.
Methods: Patient level data were combined from 6 prospective randomized and single-
arm multicenter trials involving 2,132 patients treated with Endeavor
zotarolimus-eluting stents (E-ZES) and 596 patients treated with a bare metal stent
(BMS) control. All patients were prospectively followed for 5 years. The recommended
minimum duration of dual antiplatelet therapy in all trials was 3 to 6 months regardless
of stent type. An independent events committee adjudicated all events. The 2 treatment
groups were compared after adjustment for between trial variation and for individual
patient clinical and angiographic characteristics by propensity score modeling.
Results: For the first 1,268 E-ZES patients with 5-year follow-up, the cumulative
incidence of adverse events for E-ZES and BMS were: death: 5.9% vs 7.6% (adjusted
HR: 0.81, p=0.34), cardiac death: 2.4% vs 3.7% (0.83, p=0.57), MI: 3.4% vs 4.8%
(0.77, p=0.37), TLR: 7.0% vs 16.5% (0.42, p=0.001), ST (definite or probable): 0.8%
vs 1.7% (0.50, p=0.21). Outcomes were consistent across trials and within subgroups
at highest risk for adverse events. Very late TLR (Δ=1.6%) and ST (Δ=0.18%) for E-
ZES remained stable between 1 and 5 years. Final 5-year safety and efficacy results
for the entire program (N=2,132) will be presented.
Conclusion: Through 5 years available follow-up, percutaneous revascularization with
ZES compared with BMS was associated with no increased risk of death, myocardial
infarction or stent thrombosis, and a significant and durable reduction in repeat
revascularization. Final outcomes from completion of the Endeavor ZES program will
provide insight to the late-term effectiveness of E-ZES.
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Background: To evaluate the long-term efficacy of Sirolimus (SES), Paclitaxel (PES),
Everolimus (EES) and Zotarolimus-eluting stent (ZES-R/ Endeavor Resolute) on the
outcome of patients with chronic total occlusions (CTO).
Methods: A total of 378 patients with 414 CTO lesions (male 72.8%, mean age 69.9
yrs, LAD 49.5%, LCX 21.0%, RCA 26.6%, Others 2.9%) were treated with SES (102
patients 118 lesions, lesion length 36.1±12.9mm, stent length 41.7±15.6mm), PES (108
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